<p>Bicycle Therapeutics PLC 赞助的 ADR (NASDAQ:BCYC - 获取免费报告) 的股价在周一交易中下跌了 8.8%，原因是加拿大皇家银行将该股票的评级从 “跑赢大盘” 下调至 “行业表现”。加拿大皇家银行现在对该股票的目标价为 11.00 美元，低于之前的 27.00 美元。Bicycle Therapeutics 的交易最低价为 7.40 美元，最后交易价为 7.36 美元。在交易中，共成交 168,478 股，较平均交易量 309,490 股下降了 46%。该股票之前的收盘价为 8.07 美元。</p>
<p>其他一些研究分析师也最近对该股票发表了看法。摩根士丹利将 Bicycle Therapeutics 的目标价从 17.00 美元下调至 13.00 美元，并在 8 月 12 日的研究报告中对该股票给予了 “等权重” 评级。Oppenheimer 在 8 月 11 日的研究报告中重申了 “跑赢大盘” 评级，并对 Bicycle Therapeutics 的目标价设定为 44.00 美元（低于之前的 48.00 美元）。Citizens Jmp 将 Bicycle Therapeutics 的目标价从 10.00 美元上调至 12.00 美元，并在周五的研究报告中给予该公司 “市场跑赢大盘” 评级。JMP Securities 在周五的研究报告中对 Bicycle Therapeutics 设定了 12.00 美元的目标价。最后，Weiss Ratings 在 10 月 14 日的研究报告中重申了对 Bicycle Therapeutics 的 “卖出（d-）” 评级。七位研究分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 19.80 美元。</p>
<p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
<p><strong>阅读我们关于 Bicycle Therapeutics 的最新报告</strong></p>
<h2>Bicycle Therapeutics 的内部交易</h2>
<p>在其他 Bicycle Therapeutics 的新闻中，首席执行官 Kevin Lee 于 10 月 3 日星期五出售了 3,231 股该股票。股份以平均价格 8.41 美元出售，总价值为 27,172.71 美元。出售后，首席执行官直接持有该公司 475,310 股，价值 3,997,357.10 美元。这代表了其持股比例的 0.68% 的下降。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接获取。在过去 90 天内，内部人士已出售价值 71,738 美元的 8,527 股公司股票。公司内部人士持有该公司 22.90% 的股份。</p>
<h2>对 Bicycle Therapeutics 的对冲基金看法</h2>
<p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Armistice Capital LLC 在第二季度将其在 Bicycle Therapeutics 的持股增加了 4.8%。Armistice Capital LLC 现在持有 2,800,000 股该公司的股票，价值 19,460,000 美元，此前在上个季度购买了额外的 128,000 股。Westfield Capital Management Co. LP 在第二季度将其在 Bicycle Therapeutics 的持股增加了 4.6%。Westfield Capital Management Co. LP 现在持有 2,780,491 股该公司的股票，价值 19,324,000 美元，此前在上个季度购买了额外的 123,186 股。Long Focus Capital Management LLC 在第一季度将其在 Bicycle Therapeutics 的持股增加了 138.2%。Long Focus Capital Management LLC 现在持有 1,293,753 股该公司的股票，价值 10,984,000 美元，此前在上个季度购买了额外的 750,661 股。Candriam S.C.A. 在第一季度将其在 Bicycle Therapeutics 的持股增加了 10.8%。Candriam S.C.A. 现在持有 1,205,207 股该公司的股票，价值 10,232,000 美元，此前在上个季度购买了额外的 117,331 股。最后，Tybourne Capital Management HK Ltd. 在第二季度将其在 Bicycle Therapeutics 的持股增加了 72.4%。Tybourne Capital Management HK Ltd. 现在持有 993,743 股该公司的股票，价值 6,907,000 美元，此前在上个季度购买了额外的 417,400 股。机构投资者持有该公司 86.15% 的股份。</p>
<h2>Bicycle Therapeutics 股价下跌 8.6%</h2>
<p>该公司的 50 日移动平均线为 7.66 美元，200 日移动平均线为 7.88 美元。该公司的市值为 5.1114 亿美元，市盈率为 -2.04，贝塔值为 1.47。</p>
<p>Bicycle Therapeutics (NASDAQ:BCYC - 获取免费报告) 最近于 8 月 8 日发布了其财报。该公司报告本季度每股收益为 -1.14 美元，低于共识预期的 -0.95 美元，差额为 -0.19 美元。Bicycle Therapeutics 的净利润率为 -884.51%，股本回报率为 -36.05%。该公司本季度的收入为 290 万美元，而共识预期为 943 万美元。分析师预计 Bicycle Therapeutics PLC 赞助的 ADR 本年度将发布 -3.06 美元的每股收益。</p>
<h2>Bicycle Therapeutics 公司简介</h2>
<p>（获取免费报告）</p>
<p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 阶段临床试验的自行车毒素结合物（BTC），用于治疗高表达 nectin-4 的肿瘤；BT5528，一种正在进行 I/II 阶段临床试验的 BTC，用于治疗表达 Ephrin A 型受体 2 的肿瘤；BT7480，一种正在进行 I/II 阶段的 Bicycle TICA 分子，针对 Nectin-4 并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的 Bicycle TICA 分子，处于临床前试验阶段。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Bicycle Therapeutics 更好</li>
<li>消费品股票解析</li>
<li>1.34 亿美元的内部交易：这对 KMI、ISRG 和 QS 可能意味着什么</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>3 只股票闪现买入信号，回购总额达 85 亿美元</li>
<li>使用 MarketBeat 股息收益率计算器</li>
<li>Freshpet 内部人士称已触底：现在是买入时机</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Bicycle Therapeutics 吗？</h2>
<p>在你考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bicycle Therapeutics 并不在名单上。</p>
<p>虽然 Bicycle Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

BCYC

<p>Bicycle Therapeutics（纳斯达克代码：BCYC）股价下跌 8.8%，因加拿大皇家银行将该股票评级从 “跑赢大盘” 下调至 “行业表现”，并将目标价从 27 美元下调至 11 美元。其他分析师也调整了他们的评级，摩根士丹利将目标价从 17 美元下调至 13 美元。该股票最低交易价为 7.40 美元，市值为 5.1114 亿美元。公司报告的季度每股收益为-1.14 美元，未能达到预期，且共识评级为 “适度买入”，目标价为 19.80 美元</p>

<p>Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC - Get Free Report)'s stock price fell 8.8% during trading on Monday after Royal Bank Of Canada downgraded the stock from an outperform rating to a sector perform rating. Royal Bank Of Canada now has a $11.00 price target on the stock, down from their previous price target of $27.00. Bicycle Therapeutics traded as low as $7.40 and last traded at $7.36. 168,478 shares changed hands during trading, a decline of 46% from the average session volume of 309,490 shares. The stock had previously closed at $8.07.</p>
<div class="lb-trans"><p>Bicycle Therapeutics PLC 赞助的 ADR (NASDAQ:BCYC - 获取免费报告) 的股价在周一交易中下跌了 8.8%，原因是加拿大皇家银行将该股票的评级从 “跑赢大盘” 下调至 “行业表现”。加拿大皇家银行现在对该股票的目标价为 11.00 美元，低于之前的 27.00 美元。Bicycle Therapeutics 的交易最低价为 7.40 美元，最后交易价为 7.36 美元。在交易中，共成交 168,478 股，较平均交易量 309,490 股下降了 46%。该股票之前的收盘价为 8.07 美元。</p>
</div><p>A number of other research analysts have also recently weighed in on the stock. Morgan Stanley dropped their target price on shares of Bicycle Therapeutics from $17.00 to $13.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Tuesday, August 12th. Oppenheimer reiterated an &#34;outperform&#34; rating and issued a $44.00 target price (down from $48.00) on shares of Bicycle Therapeutics in a research note on Monday, August 11th. Citizens Jmp boosted their target price on shares of Bicycle Therapeutics from $10.00 to $12.00 and gave the company a &#34;market outperform&#34; rating in a research note on Friday. JMP Securities set a $12.00 target price on shares of Bicycle Therapeutics in a research note on Friday. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Bicycle Therapeutics in a research note on Tuesday, October 14th. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $19.80.</p>
<div class="lb-trans"><p>其他一些研究分析师也最近对该股票发表了看法。摩根士丹利将 Bicycle Therapeutics 的目标价从 17.00 美元下调至 13.00 美元，并在 8 月 12 日的研究报告中对该股票给予了 “等权重” 评级。Oppenheimer 在 8 月 11 日的研究报告中重申了 “跑赢大盘” 评级，并对 Bicycle Therapeutics 的目标价设定为 44.00 美元（低于之前的 48.00 美元）。Citizens Jmp 将 Bicycle Therapeutics 的目标价从 10.00 美元上调至 12.00 美元，并在周五的研究报告中给予该公司 “市场跑赢大盘” 评级。JMP Securities 在周五的研究报告中对 Bicycle Therapeutics 设定了 12.00 美元的目标价。最后，Weiss Ratings 在 10 月 14 日的研究报告中重申了对 Bicycle Therapeutics 的 “卖出（d-）” 评级。七位研究分析师对该股票给予了买入评级，四位给予了持有评级，一位给予了卖出评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “适度买入”，共识目标价为 19.80 美元。</p>
</div><p>Get <strong>Bicycle Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Bicycle Therapeutics</strong> 的提醒：</p>
</div><p><strong>Read Our Latest Report on Bicycle Therapeutics</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 Bicycle Therapeutics 的最新报告</strong></p>
</div><h2>Insider Transactions at Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 的内部交易</h2>
</div><p>In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the sale, the chief executive officer directly owned 475,310 shares in the company, valued at $3,997,357.10. This represents a 0.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last 90 days, insiders have sold 8,527 shares of company stock valued at $71,738. Corporate insiders own 22.90% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Bicycle Therapeutics 的新闻中，首席执行官 Kevin Lee 于 10 月 3 日星期五出售了 3,231 股该股票。股份以平均价格 8.41 美元出售，总价值为 27,172.71 美元。出售后，首席执行官直接持有该公司 475,310 股，价值 3,997,357.10 美元。这代表了其持股比例的 0.68% 的下降。该交易已在向 SEC 提交的文件中披露，文件可通过此超链接获取。在过去 90 天内，内部人士已出售价值 71,738 美元的 8,527 股公司股票。公司内部人士持有该公司 22.90% 的股份。</p>
</div><h2>Hedge Funds Weigh In On Bicycle Therapeutics</h2>
<div class="lb-trans"><h2>对 Bicycle Therapeutics 的对冲基金看法</h2>
</div><p>Several institutional investors and hedge funds have recently made changes to their positions in the business. Armistice Capital LLC grew its holdings in shares of Bicycle Therapeutics by 4.8% during the 2nd quarter. Armistice Capital LLC now owns 2,800,000 shares of the company's stock valued at $19,460,000 after purchasing an additional 128,000 shares during the last quarter. Westfield Capital Management Co. LP grew its holdings in shares of Bicycle Therapeutics by 4.6% during the 2nd quarter. Westfield Capital Management Co. LP now owns 2,780,491 shares of the company's stock valued at $19,324,000 after purchasing an additional 123,186 shares during the last quarter. Long Focus Capital Management LLC grew its holdings in shares of Bicycle Therapeutics by 138.2% during the 1st quarter. Long Focus Capital Management LLC now owns 1,293,753 shares of the company's stock valued at $10,984,000 after purchasing an additional 750,661 shares during the last quarter. Candriam S.C.A. grew its holdings in shares of Bicycle Therapeutics by 10.8% during the 1st quarter. Candriam S.C.A. now owns 1,205,207 shares of the company's stock valued at $10,232,000 after purchasing an additional 117,331 shares during the last quarter. Finally, Tybourne Capital Management HK Ltd. grew its holdings in shares of Bicycle Therapeutics by 72.4% during the 2nd quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company's stock valued at $6,907,000 after purchasing an additional 417,400 shares during the last quarter. Institutional investors own 86.15% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近对该公司的持仓进行了调整。Armistice Capital LLC 在第二季度将其在 Bicycle Therapeutics 的持股增加了 4.8%。Armistice Capital LLC 现在持有 2,800,000 股该公司的股票，价值 19,460,000 美元，此前在上个季度购买了额外的 128,000 股。Westfield Capital Management Co. LP 在第二季度将其在 Bicycle Therapeutics 的持股增加了 4.6%。Westfield Capital Management Co. LP 现在持有 2,780,491 股该公司的股票，价值 19,324,000 美元，此前在上个季度购买了额外的 123,186 股。Long Focus Capital Management LLC 在第一季度将其在 Bicycle Therapeutics 的持股增加了 138.2%。Long Focus Capital Management LLC 现在持有 1,293,753 股该公司的股票，价值 10,984,000 美元，此前在上个季度购买了额外的 750,661 股。Candriam S.C.A. 在第一季度将其在 Bicycle Therapeutics 的持股增加了 10.8%。Candriam S.C.A. 现在持有 1,205,207 股该公司的股票，价值 10,232,000 美元，此前在上个季度购买了额外的 117,331 股。最后，Tybourne Capital Management HK Ltd. 在第二季度将其在 Bicycle Therapeutics 的持股增加了 72.4%。Tybourne Capital Management HK Ltd. 现在持有 993,743 股该公司的股票，价值 6,907,000 美元，此前在上个季度购买了额外的 417,400 股。机构投资者持有该公司 86.15% 的股份。</p>
</div><h2>Bicycle Therapeutics Trading Down 8.6%</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 股价下跌 8.6%</h2>
</div><p>The company's fifty day moving average is $7.66 and its 200 day moving average is $7.88. The company has a market cap of $511.14 million, a P/E ratio of -2.04 and a beta of 1.47.</p>
<div class="lb-trans"><p>该公司的 50 日移动平均线为 7.66 美元，200 日移动平均线为 7.88 美元。该公司的市值为 5.1114 亿美元，市盈率为 -2.04，贝塔值为 1.47。</p>
</div><p>Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last released its earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing the consensus estimate of ($0.95) by ($0.19). Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. The business had revenue of $2.90 million for the quarter, compared to the consensus estimate of $9.43 million. Analysts anticipate that Bicycle Therapeutics PLC Sponsored ADR will post -3.06 EPS for the current year.</p>
<div class="lb-trans"><p>Bicycle Therapeutics (NASDAQ:BCYC - 获取免费报告) 最近于 8 月 8 日发布了其财报。该公司报告本季度每股收益为 -1.14 美元，低于共识预期的 -0.95 美元，差额为 -0.19 美元。Bicycle Therapeutics 的净利润率为 -884.51%，股本回报率为 -36.05%。该公司本季度的收入为 290 万美元，而共识预期为 943 万美元。分析师预计 Bicycle Therapeutics PLC 赞助的 ADR 本年度将发布 -3.06 美元的每股收益。</p>
</div><h2>Bicycle Therapeutics Company Profile</h2>
<div class="lb-trans"><h2>Bicycle Therapeutics 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.</p>
<div class="lb-trans"><p>Bicycle Therapeutics plc 是一家临床阶段的生物制药公司，开发一类针对美国和英国现有治疗手段未能满足的疾病的药物。其产品管线包括 BT8009，一种正在进行 I/II/III 阶段临床试验的自行车毒素结合物（BTC），用于治疗高表达 nectin-4 的肿瘤；BT5528，一种正在进行 I/II 阶段临床试验的 BTC，用于治疗表达 Ephrin A 型受体 2 的肿瘤；BT7480，一种正在进行 I/II 阶段的 Bicycle TICA 分子，针对 Nectin-4 并激活 CD137；以及 BT7455，一种针对 Ephrin A 型受体 2 和 CD137 的 Bicycle TICA 分子，处于临床前试验阶段。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Bicycle Therapeutics</li>
<li>Consumer Staples Stocks, Explained</li>
<li>$134M in Insider Moves: What It Might Mean for KMI, ISRG and QS</li>
<li>Using the MarketBeat Dividend Tax Calculator</li>
<li>3 Stocks Flashing Buy Signals With $8.5 Billion in Buybacks</li>
<li>Using the MarketBeat Dividend Yield Calculator</li>
<li>Freshpet Insiders Called the Bottom: Now It’s Time to Buy</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Bicycle Therapeutics 更好</li>
<li>消费品股票解析</li>
<li>1.34 亿美元的内部交易：这对 KMI、ISRG 和 QS 可能意味着什么</li>
<li>使用 MarketBeat 股息税计算器</li>
<li>3 只股票闪现买入信号，回购总额达 85 亿美元</li>
<li>使用 MarketBeat 股息收益率计算器</li>
<li>Freshpet 内部人士称已触底：现在是买入时机</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Bicycle Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Bicycle Therapeutics 吗？</h2>
</div><p>Before you consider Bicycle Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Bicycle Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicycle Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Bicycle Therapeutics 并不在名单上。</p>
</div><p>While Bicycle Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Bicycle Therapeutics 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Bicycle Therapeutics（纳斯达克股票代码：BCYC）在分析师下调评级后，股价下跌了 8.8%